Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer’s.
Researchers have found that ketamine’s antidepressant effects target astroglia, a type of brain support cell, rather than neurons, challenging conventional views.